Application No. 10/518,815

Response Dated: March 12, 2007

Reply to Restriction Requirement of February 21, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/518,815	First Named Inventor: Bailey et al.
371 Filing Date: Dec. 20, 2004	Attorney Docket No.: 100729-1P US
Examiner: MOORE, Susanna	Group Art Unit: 1624
Customer No.: 22466	Confirmation No.: 8233
Title: Novel purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases	
associated with cysteine protease activity	

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO THE RESTRICTION REQUIREMENT

Sir:

The present Response is filed in regard to the Restriction Requirement dated February 21, 2007 in connection with the above-identified patent application.

In the Restriction Requirement, the Examiner restricted pending claims into four groups:

Group (I), claim(s) 1-5, 6(part) and 7-13, drawn to compounds of formula (I), wherein X = nitrogen and Y= carbon, methods of use and compositions thereof.

Group (II), claims) 1, 3-5, 6(part) and 7-13, drawn to drawn to compounds of formula (I), wherein X= nitrogen and Y= nitrogen, methods of use and compositions thereof.

Group (III), claim(s) 1, 3-5, 6(part) and 7-13, drawn to compounds of formula (I), wherein X = carbon and Y= carbon, methods of use and compositions thereof.

Group (IV), claim(s) 1, 3-5, 6(part) and 7-13, drawn to compounds of formula (I), wherein X= carbon and Y= nitrogen, methods of use and compositions thereof.

Applicants elect Group (I) with traverse.

Examiner mentioned in the Office Action that a telephone call was made to Laura Madden on January 21, 2007 to request an oral election. Applicants are puzzled by Examiner's phone call to Ms. Madden since Ms. Madden was not an attorney of record and was not authorized to act on behalf of Applicants at that time.

Application No. 10/518,815

Response Dated: March 12, 2007

Reply to Restriction Requirement of February 21, 2007

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100729-1P US.

Respectfully submitted, /Jianzhong SHEN, Reg.#48076 /

Name: Jianzhong Shen
Dated: 3/12/2007
Reg. No.: 48076
Phone No.: 302-886-8854
Global Intellectual Property, Patents,
AstraZeneca.

1800 Concord Pike, Wilmington, DE-19850-5437